This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-08. Anything still debated is marked as such rather than presented as settled.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
=== Condensate microenvironment === The condensate microenvironment refers to the distinct internal physical and chemical conditions within biomolecular condensates that influence molecular behavior and biochemical activity. These environments can differ markedly from the surrounding cellular milieu in terms of material property, pH, and chemical property. Rather than acting solely as passive concentration hubs, condensates modulate their internal milieu to promote selective partitioning, regulate reaction kinetics, and enable context-specific biological functions. Experimental studies have revealed several mechanisms by which condensate microenvironments operate. The material properties of condensates have been linked to condensate composition and functions. Nucleolar condensates have been shown to maintain internal pH gradients that influence RNA processing and protein composition. Other studies have demonstrated that different nuclear condensates exhibit distinct solvent characteristics, shaping the partitioning behavior of small molecules and biochemical cofactors. Further direct evidence comes from experiments using synthetic tools to manipulate condensate material properties. One study introduced a genetically encoded peptide, killswitch, that selectively arrests condensate dynamics without disrupting their scaffolds, enabling controlled perturbation of condensate material property in live cells. This intervention altered the protein composition of transcriptional condensates and impaired their biological activity.
As of 2020, despite the group's rapid expansion, the CJNG does not necessarily control every area it is present in. It is, however, the dominant criminal actor in Jalisco, Nayarit, Colima, the port of Lázaro Cárdenas in Michoacán, the eastern state of Veracruz and in the oil-rich central region of Guanajuato, Puebla, Querétaro and Hidalgo. It is also strong, although facing stern rivalries, in the border cities of Tijuana and Juárez, Tierra Caliente – the area which covers parts of Michoacán, Guerrero, and the State of Mexico, as well as the Riviera Maya. The group has shown it may be focusing on entering the capital, after a brazen attack against Mexico City's public security secretary in June 2020. Internationally, the cartel has contacts in Colombia, Peru, Bolivia, the United States, Central America, Canada, Australia, China and Southeast Asia, which help it control large parts of marijuana, cocaine and synthetic drug trafficking in Mexico. On 31 March 2021, a show of force and a massacre of rivals was reported in the Aguililla municipality, the birthplace of "El Mencho", an avocado growing area and also a center of drug cooking within the Tierra Caliente.
{\displaystyle \Delta _{^{12}CH_{2}D_{2}}={\left({\frac {0.183798}{T}}\right)}-{\left({\frac {785.483}{T^{2}}}\right)}+\left({\frac {1056280.0}{T^{3}}}\right)+\left({\frac {9.37307\times 10^{7}}{T^{4}}}\right)-\left({\frac {8.919480\times 10^{10}}{T^{5}}}\right)+\left({\frac {9.901730\times 10^{12}}{T^{6}}}\right)}
== Medical uses == Vinblastine is a component of a number of chemotherapy regimens, including ABVD for Hodgkin lymphoma, and along with methotrexate in the treatment of aggressive fibromatosis (desmoid tumor). It is also used to treat histiocytosis according to the established protocols of the Histiocytosis Association.
=== Hypersaline environment === As sea ice forms, the water freezes into a lattice structure; this process ejects many of the salts and microbes from the ice, concentrating them in the remaining water. This high-salinity seawater is known as brine, and as more salts accumulate within the brine pockets, the remaining brine becomes more resistant to freezing. This accumulation of salts, producing a liquid environment that can remain liquid in subzero temperatures, provides a harsh-but-suitable environment for microorganisms to survive. These brine pockets maintain a very saline environment, have high concentrations of other dissolved minerals, and have a high density of microbial life. Brine salinity and concentration are directly dependent on the air temperature of the surrounding environment; as temperatures decrease, more salts become rejected from newly-formed ice, causing more salts to accumulate within the brine, and brine pockets decrease in size. This results in a hypersaline environment with dissolved salt contents which can reach up to 200 g/kg, in contrast to open seawater which has a salinity of 33-37 g/kg.
Sources: en.wikipedia.org
Two franchisees bought the chain in 1984 and they sold out to Inno-Pacific Holdings of Singapore in 1989. By that time, the number of franchises had declined to 221. Most of the remaining U. S. stores closed during the time Inno-Pacific owned the chain. Some of the remaining franchisees took Inno-Pacific to court in 2003. Before the case could come to trial, Shakey's was sold to Jacmar Companies of Alhambra, California in 2004. Jacmar had been the franchisee of 19 Shakey's restaurants. On September 30, 2024, SPAVI announced the incorporation of an American subsidiary that would own and operate and franchise stores in the United States. As of October 2018, there were 51 Shakey's Pizza restaurants in the United States - 48 of the locations are in California (all, except Oroville, are in Southern California), and two in Washington. The last location east of the Mississippi River, in Auburn, Alabama, closed in April 2019. The location in Renton, Washington closed on January 20, 2025, leaving Pasco as the only remaining Washington location. All locations closed their dining rooms in mid-March 2020 to combat the COVID-19 pandemic, with take-out service still available. Dining rooms re-opened in May 2021.
== Medical uses == Sumatriptan is indicated for the acute treatment of migraine with or without aura in adults; or the acute treatment of cluster headache in adults. Sumatriptan is effective for ending or relieving the intensity of migraine and cluster headaches. Injected sumatriptan is more effective than other formulations. Oral sumatriptan can be used also in the treatment of post-dural puncture headache.
=== Hydrolysis === DBNPA undergoes rapid pH-dependent hydrolysis in aqueous environments, leading to the formation of different degradation products. The C-Br bonds break down rapidly into smaller organic and inorganic byproducts when exposed to neutral to alkaline environments due to nucleophilic substitution. DBNPA can endure longer in acidic settings since the hydrolysis rate is lower. The pH has a significant impact on DBNPA's breakdown. The main degradation product at pH 5 is dibromoacetic acid (DBAA), which makes up 30.6% of all DBNPA breakdown products. The breakdown mechanism changes as the pH rises, favouring the synthesis of dibromoacetonitrile (DBAN), which dominates at pH 7 (54.5%) and pH 9 (38.6%). Ammonia, carbon dioxide, bromide ions, and cyanoacetic acid are produced by further hydrolysis in neutral or slightly alkaline conditions.
=== Recurring === Kaitlin Olson as Deborah "DJ" Vance Jr., Deborah's daughter who sells personal crafts Chris McDonald as Marty Ghilain, CEO of the Palmetto Casino Paul W. Downs as Jimmy LuSaque Jr., Deborah and Ava's manager Rose Abdoo as Josefina, Deborah's house manager Lorenza Izzo as Ruby, Ava's ex-girlfriend and an actress Megan Stalter as Kayla Schaeffer, Jimmy's inept assistant and boss's daughter Mark Indelicato as Damien, Deborah's personal assistant Poppy Liu as Kiki, Deborah's personal blackjack dealer and an employee at the Palmetto Johnny Sibilly as Wilson, a Vegas public water inspector and Marcus' love interest Angela E. Gibbs as Robin, Marcus' mother Jane Adams as Nina Daniels, Ava's mother Louis Herthum as Dennis Daniels, Ava's father who is recovering from a stroke Amanda Payton as Jackie, one of DJ's friends Joe Mande as Ray, a front desk clerk at the Palmetto Danielle Schneider as Rina, Marty's assistant Lauren Weedman as Jo Pezzimenti, the mayor of Las Vegas
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.